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cardiovascular events in patients with SCAD 
depends on various factors, such as age, risk 
factor control, left ventricular function, kidney 
dysfunction, presence of angina, or the mod‑
el of patient care.2-5 Treatment strategies may 
INTRODUCTION Stable coronary artery dis‑
ease (SCAD) is a growing global medical and 
social problem1 due to population aging and 
increasing survival of patients with acute cor‑
onary syndromes. The risk of major adverse 
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ABSTRACT
INTRODUCTION An international registry of ambulatory patients with stable coronary artery disease 
(CLARIFY) allows a comparison of management and outcomes in real ‑life setting.
OBJECTIVES We aimed to compare the management strategies and 5 ‑year outcomes in patients from 
Poland and from other European countries.
PATIENTS AND METHODS Stable coronary artery disease was defined as previous myocardial infarction 
(MI) or revascularization, coronary stenosis greater than 50%, or documented symptomatic myocardial 
ischemia. Patients were followed on an annual basis for 5 years.
RESULTS Among the total of 32 703 patients, 1000 were enrolled in Poland, and 17 326 in other European 
countries. Polish patients were younger, with a higher proportion of women, smokers, and patients with 
previous MI, dyslipidemia, and hypertension. Patients in both cohorts received adequate medical treatment, 
with more Polish patients receiving β ‑blockers. Blood pressure and lipid control to target was similar and 
remained low in both cohorts. Diabetes control and successful smoking cessation rates were lower in Poland 
than in other European countries. Polish patients more often underwent percutaneous coronary intervention. 
All ‑cause (8.5% vs 7.9%; P = 0.81) and cardiovascular death rates (5.3% vs 4.9%; P = 0.82) did not differ 
between the groups, but fatal or nonfatal MI occurred more often in the Polish cohort (5% vs 3.1%; P = 0.006). 
Angina control was better in Poland than in other European countries (Canadian Cardiovascular Society class 
II‑IV, 11.5% vs 15.8% of patients; P <0.001).
CONCLUSIONS Risk factor control was insufficient both in patients from Poland and in those from other 
European countries. The more frequent use of revascularization in Polish patients was not linked to improved 
outcomes, but, together with more extensive prescription of β ‑blockers, might have contributed to better 
angina control.
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revascularization procedures, analyzed the effica‑
cy of risk factor control, and assessed clinical out‑
comes at 5 years, including the first occurrence of 
cardiovascular death or nonfatal MI, cardiovascu‑
lar death, nonfatal MI or nonfatal stroke, as well 
as all ‑cause and cardiovascular death and MI (fa‑
tal or nonfatal). We also assessed changes in the 
prevalence of angina at baseline and at 5 ‑year 
follow ‑up in both groups.
Statistical analysis Statistical analysis of data 
was performed by an independent statistics cen‑
ter (Robertson Centre for Biostatistics, University 
of Glasgow, United Kingdom). Continuous vari‑
ables were presented as mean (SD) or median and 
interquartile range, depending on data distribu‑
tion. Categorical data were presented as number 
and percentage. Clinical outcomes were analyzed 
with unadjusted Cox proportional hazards regres‑
sion models in the R software, version 3.4.1 (The 
R Project for Statistical Computing).10,11 Ancillary 
analyses were performed locally by an investiga‑
tor not involved in the study, using the summa‑
ry independent t test for continuous data, and 
the χ2 test for categorical data.
RESULTS Patient characteristics Among the to‑
tal of 32 703 patients, exactly 1000 were enrolled 
in Poland, and 17 326 in 23 European countries 
included in the study. The list of participating Eu‑
ropean countries and respective number of pa‑
tients recruited are presented in Supplementary 
material, Table S1. Baseline patient characteristics 
are given in TABLE 1. Polish patients were young‑
er, with a higher proportion of women, current 
or former smokers, and patients with a history 
of MI, dyslipidemia, and hypertension. At base‑
line, a similar proportion of patients in both co‑
horts had Canadian Cardiovascular Society (CCS) 
class II to IV angina (Polish patients, 20.3% vs pa‑
tients from other European countries, 20.7%).
Medical therapy Medical therapies used at base‑
line and at the end of study are shown in TABLE 2. 
In general, most patients in both cohorts re‑
ceived guideline ‑recommended medical treatment 
throughout the study.12 Over 90% of patients re‑
ceived antiplatelet treatment with either aspirin 
or other agent (mostly clopidogrel). Similarly, over 
90% of patients received a lipid ‑lowering drug (pre‑
dominantly a statin). Angiotensin ‑converting en‑
zyme inhibitors (ACEIs) and β ‑blockers were more 
frequently used in the Polish cohort, while the use 
of angiotensin receptor blockers and ivabradine 
was more frequent in the European cohort.
In patients with different risk factors at base‑
line, target values for blood pressure were 
achieved in similar, small number of patients 
(Polish cohort, 64.4% vs European cohort, 65% 
of hypertensive patients with blood pressure 
<140/90 mm Hg at 5 years; P = 0.83), similarly 
to lipid control (Polish cohort, 18.4% vs Europe‑
an cohort, 19% of patients with dyslipidemia and 
low ‑density lipoprotein [LDL] cholesterol levels 
differ between regions and countries and may 
affect clinical outcomes.6
In addition, over the last decades, the clini‑
cal profile of patients with SCAD has consider‑
ably evolved.7 The CLARIFY registry (Prospec‑
tive Observational Longitudinal Registry of Pa‑
tients with Stable Coronary Artery Disease) was 
an international registry of ambulatory patients, 
which aimed to describe the contemporary pop‑
ulation of patients with SCAD, identify gaps be‑
tween evidence ‑based recommendations and actu‑
al treatment, and establish determinants of out‑
come.8,9 The aim of the current analysis was to 
compare management strategies and long ‑term 
clinical outcomes between patients from Poland 
and other European countries.
PATIENTS AND METHODS Study design The ra‑
tionale, design, and baseline characteristics of 
the entire CLARIFY population have been pub‑
lished elsewhere.9 CLARIFY participants were en‑
rolled from 45 countries worldwide between No‑
vember 2009 and June 2010. In order to be eligi‑
ble for the study, the patients had to fulfill at least 
one of the following criteria: previous myocardi‑
al infarction (MI), history of myocardial revas‑
cularization (coronary artery bypass surgery or 
percutaneous coronary intervention [PCI]), cor‑
onary stenosis greater than 50%, or document‑
ed symptomatic myocardial ischemia. The main 
exclusion criteria were hospitalization for cardio‑
vascular disease within the previous 3 months, 
planned revascularization, and serious conditions 
that might affect the 5 ‑year outcome.
In each country, study sites were selected by 
national coordinators according to predefined cri‑
teria that aimed to reflect the burden of SCAD. 
Participating physicians were asked to manage 
patients according to their usual practice. Each 
physician was requested to enroll 10 to 15 con‑
secutive patients. In each country, the goal was 
to recruit approximately 25 patients per million 
inhabitants. Patients were followed on an annual 
basis for 5 years. Data were collected using stan‑
dardized electronic case ‑report forms available 
in a local language. The data were centrally veri‑
fied for accuracy and completeness. Five percent 
of centers were randomly selected for complete 
on ‑site audit.9
The CLARIFY registry was conducted accord‑
ing to the principles specified in the Declaration 
of Helsinki. The study was approved by the Eth‑
ics Committees and regulatory agencies accord‑
ing to national and local legal requirements. 
All participants gave a written informed con‑
sent before entering the study. CLARIFY is reg‑
istered in the ISRCTN registry of clinical trials 
(IRSCTN43070564).
Clinical outcomes In the current analysis, we 
compared management strategies and 5 ‑year out‑
comes between patients recruited in Poland and 
in the European cohort excluding Poland. We 
compared the patterns of drug treatment and 
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TABLE 1 Baseline patient characteristics
Parameter Poland  
(n = 1000)
Other European countries 
(n = 17 326)
P value
Age, y, mean (SD) 62.1 (9.0) 64.4 (10.4) <0.001
Male sex, n (%) 729 (72.9) 13 628 (78.7) <0.001
Systolic BP, mm Hg, mean (SD) 132.7 (15.4) 132.3 (16.3) 0.45
Diastolic BP, mm Hg, mean (SD) 79.6 (9.5) 78.4 (9.7) <0.001
HR by palpation, bpm, mean (SD) 69.3 (9.4) 67.2 (10.5) <0.001
Weight, kg, mean (SD) 83.2 (13.7) 82.0 (14.1) 0.009
BMI, kg/m2, mean (SD) 28.8 (4.3) 28.3 (4.2) <0.001
Medical history, n (%)
Previous MI 668 (66.8) 10 601 (61.2) <0.001
Previous PCI 606 (60.6) 10 056 (58.0) <0.001
Previous CABG 258 (25.8) 4 339 (25.0) 0.60
Previous stroke 32 (3.2) 675 (3.9) 0.31
Previous HF hospitalization 43 (4.3) 897 (5.2) 0.24
Asthma or COPD 58 (5.8) 1 410 (8.1) 0.01
PAD 109 (10.9) 2 238 (12.9) 0.07
Risk factors, n (%)
Dyslipidemia 845 (85.4) 13 910 (80.3) <0.001
Treated hypertension 789 (78.9) 12 702 (73.3) <0.001
Diabetes 279 (27.9) 4 530 (26.2) 0.22
Smoking status Current 132 (13.2) 2 183 (12.6) <0.001
Former 559 (55.9) 8 228 (47.5)
Never 309 (30.9) 6 914 (39.9)
Provision of care, n (%)
Cardiologist 627 (62.7) 16 207 (93.8) <0.001
Noncardiologist 373 (37.3) 1070 (6.2)
Abbreviations: BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; COPD, chronic 
obstructive pulmonary disease; HF, heart failure; HR, heart rate; MI, myocardial infarction; PAD, peripheral artery 
disease; PCI, percutaneous coronary intervention
TABLE 2 Medical therapy at baseline and at the end of study (5 years)
Drug class Baseline At 5 yearsa
Poland  
(n = 1000)
Other European 
countries  
(n = 17 326)
Poland  
(n = 866)
Other European 
countries  
(n = 11 374)
Aspirin 952 (95.2) 14 878 (85.9) 766 (88.5) 8489 (80.2)
Other antiplatelet drug 197 (19.7) 5 850 (33.8) 157 (18.1) 2616 (24.7)
Dual antiplatelet therapy 168 (16.8) 4 158 (24.0) 129 (14.9) 1760 (16.6)
Lipid ‑lowering drugs 958 (95.8) 16 008 (92.4) 815 (94.1) 9537 (90.0)
Statinsb 883 (92.2) 14 314 (89.4) 731 (89.7) 8373 (87.8)
β ‑Blockers 903 (90.3) 13 508 (78.0) 764 (88.2) 8006 (75.6)
Calcium antagonists 268 (26.8) 4 547 (26.3) 262 (30.3) 2970 (28.0)
Ivabradine 41 (4.1) 2836 (16.4) 70 (8.1) 2641 (24.9)
ACEIs 752 (75.2) 9 619 (55.5) 611 (70.6) 5600 (52.9)
ARBs 175 (17.5) 4 374 (25.3) 169 (19.5) 2860 (27.0)
Data are presented as number (percentage) of patients.
a Percentages provided for patients with no missing data
b Percentage of patients receiving lipid ‑lowering drugs
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ARB, angiotensin receptor blocker
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Revascularization Incident revascularization 
rates are shown in FIGURE 2. Revascularization was 
more frequent in the Polish cohort than in the Eu‑
ropean cohort (13.2% vs 8.6%, respectively; P 
<0.001). The difference in myocardial revascu‑
larization rates resulted from a more frequent 
use of PCI in the Polish cohort (11.9% vs 7.3%, 
<1.8 mmol/l [<70 mg/dl] at 5 years; P = 0.83). Di‑
abetes control (glycated hemoglobin A1c <7%) was 
worse in the Polish cohort (9.3% vs 20.4% in the 
European cohort; P <0.001). The success rate for 
smoking cessation was also worse in Poland than 
in other European countries (21.6% vs 28.4%, re‑
spectively; P = 0.13) (FIGURE 1).
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FIGURE 1 Risk factor 
control at 5 ‑year follow‑
‑up. Targets achieved in 
patients with respective 
risk factors at baseline. 
Abbreviations: EUR, other 
European countries; 
HbA1c, glycated 
hemoglobin A1c; LDL ‑C, 
low ‑density lipoprotein 
cholesterol; PL, Poland; 
others, see TABLES 1 and 3
FIGURE 2  
Revascularization 
procedures during 
follow‑up 
Abbreviations: see 
TABLE 1, TABLE 2, and 
FIGURE 1
TABLE 3 Clinical outcomes
Outcome Events 
(PL compared  
with EUR; %)
HR (95% CI) P value
CV death or nonfatal MI 8.8 vs 7.2 1.12 (0.90–1.39) 0.3
CV death, nonfatal MI, or nonfatal stroke 10.5 vs 8.6 1.12 (0.92–1.37) 0.26
All ‑cause deatha 8.5 vs 7.9 0.97 (0.78–1.21) 0.81
CV deatha 5.3 vs 4.9 0.97 (0.73–1.28) 0.82
Non ‑CV deatha 3.2 vs 2.9 0.98 (0.69–1.40) 0.92
MI (fatal or nonfatal) 5.0 vs 3.1 1.51 (1.13–2.01) 0.006
Stroke (fatal or nonfatal) 2.7 vs 2.2 1.14 (0.77–1.69) 0.5
a For all death outcomes, the HR values are <1 despite higher proportion of patients experiencing the events in 
the Polish cohort than in the European cohort. This is due to the fact that the percent of events is only comparable 
between country groupings if the average follow ‑up time is the same. There were more dropouts in other European 
countries than in Poland, and therefore the time of event accrual was shorter in the former than in the latter.
Abbreviations: CV, cardiovascular; HR, hazard ratio; others, see TABLE 1 and FIGURE 1
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of antihypertensive drugs in both groups, only 
two ‑thirds of patients with hypertension achieved 
target blood pressure values recommended by 
the guidelines.13 Lipid control in both cohorts was 
poor, with less than 20% of patients with dyslip‑
idemia reaching the conventional target of LDL 
cholesterol concentration values below 1.8 mmol/l 
(70 mg/dl). Diabetes control was also inadequate, 
and significantly worse in Poland than in other 
European countries. Among patients who smoked 
at baseline, only about one ‑fourth stopped smok‑
ing during the follow ‑up. Myocardial revascular‑
ization was more common in Polish patients due 
to a more extensive use of PCI during the study, 
reflecting a good access to invasive treatment in 
Poland.14 All outcomes, including all ‑cause and 
cardiovascular death, stroke, and a combination 
of cardiovascular death and MI, as well as cardio‑
vascular death, MI, and stroke, did not differ be‑
tween the groups, except for a higher incidence 
of MI in Polish patients. At the end of the 5 ‑year 
follow ‑up, the prevalence of CCS class II–IV an‑
gina was significantly lower in the Polish cohort 
than in the European one.
Medical therapy Patients in both groups received 
medical therapy according to the European Soci‑
ety of Cardiology (ESC) guidelines12 throughout 
respectively; P <0.001), while the use of coronary 
artery bypass surgery was equally low in both 
groups (1.4% vs 1.4%, respectively; P = 0.88).
Clinical outcomes Clinical outcomes are present‑
ed in TABLE 3 and FIGURE 3. There was no difference in 
the combined double endpoint including cardio‑
vascular death and nonfatal MI between patients 
from Poland and from other European countries 
(8.8% vs 7.2%, respectively; P = 0.31), as well as 
in the triple endpoint including cardiovascular 
death, nonfatal MI, and nonfatal stroke (10.5% vs 
8.6%, respectively; P = 0.26). All ‑cause, cardiovas‑
cular, and noncardiovascular mortality, as well as 
stroke rate, did not differ between groups. How‑
ever, the incidence of MI was higher in the Pol‑
ish cohort (5% vs 3.1%, respectively; P = 0.006). 
At the end of follow ‑up, Polish patients had bet‑
ter angina control than patients from other Euro‑
pean countries (11.5% vs 15.8% of patients with 
CCS class II to IV angina, respectively; P <0.001) 
(FIGURE 4).
DISCUSSION We compared the treatment pat‑
terns and 5 ‑year outcomes in patients with 
SCAD enrolled in the  contemporary CLAR‑
IFY registry from Poland and other European 
countries. We found that despite the wide use 
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FIGURE 3 Comparison of clinical outcomes between the Polish and other European patients. Kaplan–Meier plots show the cumulative hazard for: 
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low (13%–16%). In our study, only one ‑fourth of 
patients quit smoking, as compared with over 
50% in EUROASPIRE IV.23 Since there is a wide 
variation in cessation rates between countries, 
these results should be interpreted with caution.24 
In general, our results reveal the need to direct 
careful attention not only to using evidence ‑based 
therapy but also to achieving targets specified in 
the guidelines, especially in ambulatory patients 
with SCAD.
A systematic review and meta ‑analysis of con‑
temporary trials of cardiovascular prevention and 
rehabilitation25 showed that participation in com‑
prehensive programs can improve the treatment 
to target of multiple risk factors, and thereby re‑
duce the rates of all ‑cause and cardiovascular mor‑
tality, MI, and stroke. In order to improve prog‑
nosis, patients with SCAD should be encouraged 
to join such programs.
Clinical outcome Over the past 2 decades, it has 
become more difficult to manage patients with 
SCAD because of increased complexity of their 
medical problems.7 At the same time, the use 
of guideline ‑based therapy has considerably in‑
creased,7 resulting in better clinical outcomes.26
Still, in patients with SCAD included in the re‑
cent ESC Pilot Registry,15 both all ‑cause and car‑
diovascular death rates were high (3.4% and 3% 
at 6 months, respectively). It is difficult to com‑
pare the outcomes between different studies due 
to differences in inclusion criteria and duration 
of follow ‑up, but assuming that the incidence of 
cardiovascular events in time is close to linear, our 
patients appeared to have better prognosis (all‑
cause death rate at 5 years, 7.9%; cardiovascular 
death rate at 5 years, 5 %) than those in the ESC 
Pilot15 and the REACH (Reduction of Athero‑
thrombosis for Continued Health) registries,27 
and similar to those in the CORONOR (Cohort 
of Norway) study18 and the SIGNIFY trial (Study 
Assessing the Morbidity–Mortality Benefits of 
the If Inhibitor Ivabradine in Patients with Cor‑
onary Artery Disease).20
Importantly, in the present study, there was 
no difference in clinical outcomes between 
the study. The proportion of patients on anti‑
platelet treatment was very high at baseline, with 
more aspirin, but less P2Y12 inhibitors in Polish 
patients, and a similar proportion of dual therapy. 
Lipid ‑lowering treatment was also administered 
in over 90% of patients, with the predominant 
use of statins. The lower use of ACEIs in the Eu‑
ropean cohort was compensated by the more fre‑
quent use of angiotensin receptor blockers. At the 
end of the study, these proportions became some‑
what lower, similarly to the findings from the ESC 
CAD pilot registry.15 The use of statins and anti‑
platelet agents in our patients was much higher 
than in the studies conducted at the beginning of 
the 21st century,16,17 and similar to that in more 
recent studies.18-20 Of note, the more frequent use 
of β ‑blockers in the Polish cohort than in the Eu‑
ropean one in our study might have partly con‑
tributed to better angina control.
Treatment -to -target approach The 2013 ESC guide‑
lines on the management of SCAD12 and the 2016 
European Guidelines on cardiovascular preven‑
tion in clinical practice21 set out clear ‑cut targets 
for several risk factors in patients with SCAD. Al‑
though the use of guideline ‑recommended med‑
ication in our study was satisfactory, and simi‑
lar to or better than in other studies,16-20 a large 
majority of patients did not reach the targets. 
Our results are generally similar to those ob‑
served in the recent EUROASPIRE IV survey (Eu‑
ropean Action on Secondary Prevention through 
Intervention to Reduce Events), conducted in 24 
European countries.22 At the 6 ‑month follow ‑up 
in the hospital arm of EUROASPIRE IV includ‑
ing patients with CAD, over 40% of patients did 
not meet the criteria for adequate blood pres‑
sure control, about 20% achieved the target LDL 
cholesterol concentration of less than 1.8 mmol/l 
(70 mg/dl), and around a half of those with diabe‑
tes had glycated hemoglobin A1c values below 7%. 
In our study, blood pressure control was some‑
what better (although still suboptimal), LDL cho‑
lesterol control was similar, and diabetes control 
was much worse than in EUROASPIRE IV. In both 
studies, the proportion of current smokers was 
FIGURE 4 Angina 
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TABLE 3 and FIGURE 1
0
5
10
15
20
25
Baseline Follow-up
PL
EUR
20.3
P <0.001
%
15.811.420.7
ORIGINAL ARTICLE Five ‑year outcomes in Polish patients: CLARIFY registry 333
β ‑blockers, it might have contributed to better 
angina control.
SUPPLEMENTARY MATERIAL 
Supplementary material is available at www.mp.pl/paim.
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the groups, except for a higher rate of MI in 
the Polish cohort, which, to some extent, might 
have driven a higher rate of PCI. Nevertheless, 
the more frequent use of PCI in Poland cannot be 
solely due to a higher MI incidence. Regardless, in 
our study, PCI had no impact on prognosis, which 
is compatible with the findings from the COUR‑
AGE trial (Clinical Outcomes Utilizing Revas‑
cularization and Aggressive Drug Evaluation).28
We have previously shown that patients man‑
aged by cardiologists might have lower rates of 
cardiovascular outcomes than those managed 
by noncardiologists.5 In the current analysis, al‑
most all patients from other European countries 
were managed by cardiologists, while about one‑
‑third of the Polish cohort were cared for by non‑
cardiologists, with no impact on the composite 
outcomes and cardiovascular death. This further 
confirms our previous hypothesis that there is no 
clear evidence that cardiologists provide superi‑
or guideline ‑based treatment, but the differences 
in outcome are most likely due to unquantifiable 
differences in patient characteristics.5
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cardiovascular outcomes.4 It is unclear wheth‑
er alleviation of angina can result in improved 
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prove the quality of life.29 In our study, the more 
extensive use of β ‑blockers and PCI in the Pol‑
ish cohort was associated with significantly bet‑
ter control of angina. This finding should be in‑
terpreted with caution, since we have no data on 
the indication for PCI (acute vs planned), and in 
addition, unidentified confounding factors can‑
not be excluded.
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in patients with SCAD in Poland and other Euro‑
pean countries.
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